Pathologic Response and Outcomes After Neoadjuvant Chemotherapy in Gastric Cancer: A NCDB Analysis
Journal of Surgical Oncology · 2026
DOI: 10.1002/jso.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2026. Verfasst von Jennifer Hwang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neoadjuvant Therapy, Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Pathologic complete response (pCR) after neoadjuvant therapy has been associated with improved survival in several malignancies, but its prognostic value in gastric cancer remains unclear.
Methods
Using the National Cancer Database, we identified non‐metastatic gastric adenocarcinoma patients diagnosed 2004–2021 treated with neoadjuvant chemotherapy followed by curative‐intent resection. Patients receiving neoadjuvant radiation were excluded. We analyzed pCR rates, overall survival (OS), and factors associated with pCR using a generalized estimating equations model. Kaplan–Meier and Cox proportional hazards models were used to assess OS. Trends in pCR over time were evaluated with time‐trend analysis.
Results
Among 7258 patients, 672 (9.3%) achieved pCR. Median OS was significantly higher in patients with pCR compared to those without (167.9 vs. 65.8 months, p < 0.001). Subgroup analysis of cT2N1 or higher stage patients revealed the highest survival in patients with both tumor and nodal pCR (median OS 181.8 months). Patients diagnosed after 2018 were more likely to achieve pCR (OR: 1.26, 95% CI: 1.07–1.49, p = 0.005), correlating with the adoption of the FLOT regimen. Completion of adjuvant therapy in patients who achieved pCR did not significantly improve OS. Conclusion pCR is associated with significantly improved OS in gastric cancer, especially when both tumoral and nodal pCR are achieved. Increasing pCR rates in recent years may reflect the uptake of modern chemotherapy regimens, underscoring the value of neoadjuvant strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
- Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
- Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
- Department of Surgery, Temple University Health System, Philadelphia, Pennsylvania, USA.
- Department of Bioinformatics and Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Jennifer Hwang, Li Zhang
Förderung
- NCI NIH HHS
Zitieren
APA
Hwang, J., Sun, J., Hunt, A., Papai, E., Zhang, L., Hasler, J. S., Porpiglia, A. S., Villano, A. M., Farma, J. M., & Greco, S. H. (2026). Pathologic Response and Outcomes After Neoadjuvant Chemotherapy in Gastric Cancer: A NCDB Analysis. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70251
Vancouver
Hwang J, Sun J, Hunt A, Papai E, Zhang L, Hasler JS, et al. Pathologic Response and Outcomes After Neoadjuvant Chemotherapy in Gastric Cancer: A NCDB Analysis. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70251
BibTeX
@article{Hwang2026,
author = {Hwang, Jennifer and Sun, James and Hunt, Alaina and Papai, Emily and Zhang, Li and Hasler, Jill S and Porpiglia, Andrea S and Villano, Anthony M and Farma, Jeffrey M and Greco, Stephanie H},
title = {Pathologic Response and Outcomes After Neoadjuvant Chemotherapy in Gastric Cancer: A NCDB Analysis},
journal = {Journal of Surgical Oncology},
year = {2026},
doi = {10.1002/jso.70251}
}
EUVIMED